CNTX · Company research
Context Therapeutics Inc. Common Stock (CNTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| New Strong Sell Stocks for October 15th | Stock markets declined following a higher-than-expected CPI inflation report. Three companies were added to the Zacks Rank #5 (Strong Sell) list due to downward earnings estimate revisions: Cadiz Inc., Cerenome Inc., and Context Therapeutics Inc. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -1 | 1 |
| New Strong Sell Stocks for October 15th | Stock markets declined following a higher-than-expected CPI inflation report. Three companies were added to the Zacks Rank #5 (Strong Sell) list due to downward earnings estimate revisions: Cadiz Inc., Cerenome Inc., and Context Therapeutics Inc. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -1 | 1 |
| New Strong Sell Stocks for October 13th | Three companies have been added to the Zacks Rank #5 (Strong Sell) list due to significant downward revisions in earnings estimates over the past 60 days. ATS Corporation, an industrial automation company, saw a 6.7% downward revision. Cango Inc., a bitcoin mining company, experienced an 18.2% downward revision. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, faced a 15% downward revision. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| New Strong Sell Stocks for October 13th | Three companies have been added to the Zacks Rank #5 (Strong Sell) list due to significant downward revisions in earnings estimates over the past 60 days. ATS Corporation, an industrial automation company, saw a 6.7% downward revision. Cango Inc., a bitcoin mining company, experienced an 18.2% downward revision. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, faced a 15% downward revision. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| Context Therapeutics (CNTX) Edges Higher as Penny Stock Holds Above $0.30 - Dynamic Hedging - https://www.dars.gov.et/ | Context Therapeutics (CNTX) Edges Higher as Penny Stock Holds Above $0.30 - Dynamic Hedging https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 10, 2026 | neutral | 0 | 0.6 |
| Can Context Therapeutics (NASDAQ:CNTX) Afford To Invest In Growth? - Simply Wall Street | Can Context Therapeutics (NASDAQ:CNTX) Afford To Invest In Growth? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 1, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga | Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move Benzinga | View source ↗ | Benzinga | Aug 6, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail | Context Therapeutics Receives Nasdaq Minimum Bid Price Notice The Globe and Mail | View source ↗ | The Globe and Mail | Aug 1, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk - Stock Titan | Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk Stock Titan | View source ↗ | Stock Titan | Jul 31, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics joins Russell 2000 and 3000 indexes - Stock Titan | Context Therapeutics joins Russell 2000 and 3000 indexes Stock Titan | View source ↗ | Stock Titan | Jul 6, 2026 | neutral | 0 | 0.6 |
| Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance | Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish Yahoo Finance | View source ↗ | Yahoo Finance | Jul 5, 2026 | neutral | 0 | 0.6 |
| CNTX Forecast — Price Target — Prediction for 2027 - TradingView | CNTX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits | CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip Stocktwits | View source ↗ | Stocktwits | Jun 15, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics Decline Means Insider Profits Down To US$237k - Simply Wall Street | Context Therapeutics Decline Means Insider Profits Down To US$237k Simply Wall Street | View source ↗ | Simply Wall Street | May 19, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative | Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials Quiver Quantitative | View source ↗ | Quiver Quantitative | Mar 23, 2026 | neutral | 0 | 0.6 |
| Context Therapeutics Inc. Common Stock (CNTX) Stock Price: Oct 8 Close $0.2990 - Gotrade | Context Therapeutics Inc. Common Stock (CNTX) Stock Price: Oct 8 Close $0.2990 Gotrade | View source ↗ | Gotrade | Feb 5, 2026 | neutral | 0 | 0.6 |
| Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance | Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation Yahoo Finance | View source ↗ | Yahoo Finance | Feb 5, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jan 12, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.